RU2015132431A3 - - Google Patents

Download PDF

Info

Publication number
RU2015132431A3
RU2015132431A3 RU2015132431A RU2015132431A RU2015132431A3 RU 2015132431 A3 RU2015132431 A3 RU 2015132431A3 RU 2015132431 A RU2015132431 A RU 2015132431A RU 2015132431 A RU2015132431 A RU 2015132431A RU 2015132431 A3 RU2015132431 A3 RU 2015132431A3
Authority
RU
Russia
Application number
RU2015132431A
Other languages
Russian (ru)
Other versions
RU2745601C2 (ru
RU2015132431A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2015132431(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2015132431A3 publication Critical patent/RU2015132431A3/ru
Publication of RU2015132431A publication Critical patent/RU2015132431A/ru
Application granted granted Critical
Publication of RU2745601C2 publication Critical patent/RU2745601C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2015132431A 2008-12-10 2009-12-09 Составы, содержащие антитела RU2745601C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170884.4 2008-12-10
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011127913/15A Division RU2563179C2 (ru) 2008-12-10 2009-12-09 Составы, содержащие антитела

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021107534A Division RU2021107534A (ru) 2008-12-10 2021-03-23 Составы, содержащие антитела

Publications (3)

Publication Number Publication Date
RU2015132431A3 true RU2015132431A3 (cg-RX-API-DMAC7.html) 2018-12-24
RU2015132431A RU2015132431A (ru) 2018-12-24
RU2745601C2 RU2745601C2 (ru) 2021-03-29

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015132431A RU2745601C2 (ru) 2008-12-10 2009-12-09 Составы, содержащие антитела
RU2011127913/15A RU2563179C2 (ru) 2008-12-10 2009-12-09 Составы, содержащие антитела

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2011127913/15A RU2563179C2 (ru) 2008-12-10 2009-12-09 Составы, содержащие антитела

Country Status (31)

Country Link
US (3) US20110236398A1 (cg-RX-API-DMAC7.html)
EP (4) EP2196476A1 (cg-RX-API-DMAC7.html)
JP (5) JP6143416B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170044211A (cg-RX-API-DMAC7.html)
CN (3) CN102245639B (cg-RX-API-DMAC7.html)
AU (1) AU2009324371B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922730A2 (cg-RX-API-DMAC7.html)
CA (1) CA2745938C (cg-RX-API-DMAC7.html)
CL (1) CL2011001406A1 (cg-RX-API-DMAC7.html)
CO (1) CO6361952A2 (cg-RX-API-DMAC7.html)
CY (2) CY1117735T1 (cg-RX-API-DMAC7.html)
DK (2) DK2376533T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011192A (cg-RX-API-DMAC7.html)
ES (2) ES2579835T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20160754T1 (cg-RX-API-DMAC7.html)
HU (2) HUE056626T2 (cg-RX-API-DMAC7.html)
IL (3) IL264316B2 (cg-RX-API-DMAC7.html)
LT (1) LT3072906T (cg-RX-API-DMAC7.html)
MA (1) MA33023B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011006242A (cg-RX-API-DMAC7.html)
MY (2) MY166050A (cg-RX-API-DMAC7.html)
NZ (1) NZ592918A (cg-RX-API-DMAC7.html)
PE (1) PE20120342A1 (cg-RX-API-DMAC7.html)
PL (2) PL3072906T3 (cg-RX-API-DMAC7.html)
PT (2) PT3072906T (cg-RX-API-DMAC7.html)
RU (2) RU2745601C2 (cg-RX-API-DMAC7.html)
SI (2) SI2376533T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600222B (cg-RX-API-DMAC7.html)
TN (1) TN2011000229A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010066762A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103362B (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
PH12012501742A1 (en) 2010-03-01 2022-03-21 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
JP2013544762A (ja) 2010-09-17 2013-12-19 バクスター、インターナショナル、インコーポレイテッド 弱酸性〜中性のｐＨにおける、塩化ナトリウムを有する水性製剤を介した免疫グロブリンおよび他のタンパク質の安定化
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
HUE045537T2 (hu) * 2012-03-16 2019-12-30 Regeneron Pharma PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2897977A1 (en) 2012-09-20 2015-07-29 MorphoSys AG Treatment for rheumatoid arthritis
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160002342A1 (en) * 2013-03-15 2016-01-07 Xinghang Ma Anti-prolactin receptor antibody formulations
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
CN106604744A (zh) * 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
PT3386541T (pt) * 2015-12-07 2020-10-12 Merck Patent Gmbh Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab
MA45450B1 (fr) * 2016-06-27 2021-04-30 Morphosys Ag Formulations d'anticorps anti-cd19
US20210292404A1 (en) * 2016-07-21 2021-09-23 Novartis Ag Use of il-1beta binding antibody canakinumab for treating or allevating symptoms pulmonary sarcoidosis
AU2017333367A1 (en) * 2016-09-27 2019-04-04 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
AU2018287519B2 (en) * 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CA3075711A1 (en) * 2017-09-13 2019-03-21 Novartis Ag Use of il-1 b binding antibodies for the treatment of alcoholic hepatitis
TW202003036A (zh) * 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
EP3795590A4 (en) 2018-05-17 2022-05-04 Astellas Pharma Inc. COMPLEX WITH ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND
US12065503B2 (en) 2018-10-10 2024-08-20 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
JOP20210229A1 (ar) * 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
WO2022135395A1 (zh) * 2020-12-22 2022-06-30 百奥泰生物制药股份有限公司 稳定的抗体制剂及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SK1152003A3 (en) * 2000-06-29 2003-07-01 Abbott Lab Dual specificity antibodies and methods of making and using
EP1336410A4 (en) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
JP4869064B2 (ja) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
DK2620450T3 (en) * 2005-03-08 2019-02-04 Pfizer Prod Inc Antibody Compositions against CTLA-4
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP2009513645A (ja) 2005-10-26 2009-04-02 ノバルティス アクチエンゲゼルシャフト ＩＬ−１β化合物の新規使用
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
KR20090113340A (ko) * 2007-03-22 2009-10-29 임클론 엘엘씨 안정한 항체 제제
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
HUE028408T2 (en) 2016-12-28
JP7286595B2 (ja) 2023-06-05
PT2376533T (pt) 2016-07-13
IL276622A (en) 2020-09-30
SMT201600222B (it) 2016-08-31
MX2011006242A (es) 2011-06-24
EP3072906B1 (en) 2021-09-08
WO2010066762A1 (en) 2010-06-17
PL3072906T3 (pl) 2022-01-24
JP2012511540A (ja) 2012-05-24
CN104399076B (zh) 2021-09-14
US8623367B2 (en) 2014-01-07
PT3072906T (pt) 2021-12-14
IL212922A0 (en) 2011-07-31
RU2745601C2 (ru) 2021-03-29
ES2579835T3 (es) 2016-08-17
LT3072906T (lt) 2021-12-27
IL264316B1 (en) 2023-09-01
US20110236398A1 (en) 2011-09-29
CN114225022A (zh) 2022-03-25
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
KR20170044211A (ko) 2017-04-24
ES2900624T3 (es) 2022-03-17
BRPI0922730A2 (pt) 2018-11-06
CN104399076A (zh) 2015-03-11
IL212922B (en) 2019-02-28
MA33023B1 (fr) 2012-02-01
DK3072906T3 (da) 2021-12-13
CN102245639A (zh) 2011-11-16
US20120315285A1 (en) 2012-12-13
HK1159130A1 (zh) 2012-07-27
CY1124844T1 (el) 2022-11-25
MY166050A (en) 2018-05-22
JP2023109938A (ja) 2023-08-08
CN102245639B (zh) 2014-12-24
CA2745938C (en) 2018-04-24
ZA201103362B (en) 2012-01-25
CY1117735T1 (el) 2017-05-17
KR101762966B1 (ko) 2017-07-31
JP2018168158A (ja) 2018-11-01
EP3072906A1 (en) 2016-09-28
AU2009324371B2 (en) 2013-10-10
EP2376533A1 (en) 2011-10-19
JP6143416B2 (ja) 2017-06-07
TN2011000229A1 (en) 2012-12-17
EP2376533B1 (en) 2016-03-30
HRP20160754T1 (hr) 2016-08-12
CO6361952A2 (es) 2012-01-20
IL264316B2 (en) 2024-01-01
SI3072906T1 (sl) 2022-01-31
DK2376533T3 (en) 2016-06-27
CL2011001406A1 (es) 2012-03-30
ECSP11011192A (es) 2011-08-31
RU2563179C2 (ru) 2015-09-20
PE20120342A1 (es) 2012-04-24
CA2745938A1 (en) 2010-06-17
HRP20211899T1 (hr) 2022-03-04
IL264316A (en) 2019-02-28
JP2015231997A (ja) 2015-12-24
PL2376533T3 (pl) 2016-09-30
US20200384108A1 (en) 2020-12-10
SI2376533T1 (sl) 2016-07-29
RU2015132431A (ru) 2018-12-24
EP2196476A1 (en) 2010-06-16
EP3792282A1 (en) 2021-03-17
KR20120009421A (ko) 2012-01-31
AU2009324371A1 (en) 2011-06-23
HUE056626T2 (hu) 2022-02-28
JP2020203889A (ja) 2020-12-24
RU2011127913A (ru) 2013-01-20

Similar Documents

Publication Publication Date Title
BR112016019572A2 (cg-RX-API-DMAC7.html)
BRPI0909040A2 (cg-RX-API-DMAC7.html)
BRPI0917573A2 (cg-RX-API-DMAC7.html)
BRPI0908549B8 (cg-RX-API-DMAC7.html)
BRPI0918697A2 (cg-RX-API-DMAC7.html)
BRPI0917525A2 (cg-RX-API-DMAC7.html)
BRPI0919470A2 (cg-RX-API-DMAC7.html)
BRPI0920750A2 (cg-RX-API-DMAC7.html)
BRPI0907698A2 (cg-RX-API-DMAC7.html)
BRPI0922455A2 (cg-RX-API-DMAC7.html)
BRPI0923734A2 (cg-RX-API-DMAC7.html)
BRPI0917618A8 (cg-RX-API-DMAC7.html)
BRPI0922669A2 (cg-RX-API-DMAC7.html)
BRPI0908285A2 (cg-RX-API-DMAC7.html)
BRPI0910485A2 (cg-RX-API-DMAC7.html)
BRPI0919811A2 (cg-RX-API-DMAC7.html)
BRPI0908120A2 (cg-RX-API-DMAC7.html)
BRPI0904541A8 (cg-RX-API-DMAC7.html)
BRPI0915616A2 (cg-RX-API-DMAC7.html)
BRPI0920914A2 (cg-RX-API-DMAC7.html)
BRPI0922550A2 (cg-RX-API-DMAC7.html)
BRPI0916284A2 (cg-RX-API-DMAC7.html)
BRPI0914852A2 (cg-RX-API-DMAC7.html)
BRPI0909508A2 (cg-RX-API-DMAC7.html)
CH2352018H2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191209

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20201203